Surrey Heartlands

Joint Formulary & PAD

Daridorexant - Insomnia in adults

You are here : Home > Formulary Search > Daridorexant - Insomnia in adults

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NICE
Restrictions / Comments :
Documents :
 
Webpage
NICE TA922 - Daridorexant for treating long-term insomnia - October 23
Information
Daridorexant for treating insomnia - APC briefing paper - February 2024

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Daridorexant
Indication :
Insomnia in adults
Group Name :
Keywords :
Brand Names Include :
Quviviq
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Daridorexant is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Insomnia in adults.

Committee Recommendations (2)

07 Aug 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Reminder for prescribers that referrals to specialist centres should be made for the assessment and treatment of chronic insomnia, where daridorexant may be one of the treatment options, and not for the purpose of initiating daridorexant’

07 Feb 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves daridorexant for the treatment of long-term insomnia in line with NICE TA922

A BLUE traffic light status has been agreed after Cognitive Behavioural Therapy for insomnia (CBTi) where available.

Specialist clinics will need to provide the medicines for the first 4 months (if clinically indicated), providing a review at 3 months to confirm whether treatment should be continued, and prescribing an extra month for those who will continue on treatment to allow for transfer of care to Primary Care

The length of treatment should be as short as possible.